Press "Enter" to skip to content

Human Insulin Market Outlook 2019 | Shows Industry Overview, Size, Share, Remarkable Growth Factors, Types, and Applications Forecast to 2024

Human

The “Human Insulin Market” 2019 report provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries. Human Insulin Market report also aims to provide useful and comprehensive insights into current market trends and future growth scenarios. Human Insulin market report contains information like SWOT analysis, business highlights, strength, weakness, threats and opportunities of industry.

Top Manufacturers of Human Insulin Market Are:

  • Novo Nordisk AS
  • Sanofi Aventis
  • Eli Lilly
  • Biocon
  • Pfizer
  • Julphar
  • Exir
  • Sedico
  • Wockhardt

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999756

    Market Overview:

  • The global human insulin market is expected to register a CAGR of 4.93% during the forecast period of 2019 – 2024 and is estimated to reach USD 25.7 billion by 2019.
  • Diabetes is generally considered as a lifestyle-related disease. Over time, incidences of the disease have increased outrageously, with the increase in population around the world.
  • Approximately 100 million people around the world need insulin, including all the people suffering from Type 1 diabetes and between 10-25% of people with Type 2 diabetes.
  • Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. People with Type 1 diabetes need insulin therapy, which focuses on managing blood sugar levels, along with insulin, diet, and lifestyle, in order to prevent complications.

    Scope of the Report:

  • The market is segmented by product type (basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, and biosimilar insulins) and geography.<

    Human Insulin Market Report Answers the Following Questions:

    • What will the market size and the growth rate be in 2024?
    • What are the key factors driving the global Human Insulin market?
    • What are the key market trends impacting the growth of the global Human Insulin market?
    • What are the challenges to market growth?
    • Who are the key vendors in the global Human Insulin market?
    • What are the market opportunities and threats faced by the vendors in the global Human Insulin market?
    • Trending factors influencing the market shares of the relevant regions.
    • What are the key outcomes of the five forces analysis of the global Human Insulin market?

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999756

    Key Market Trends: – Growing Obesity and Diabetes Prevalence of Type 2, Especially in Developing Countries

    The exact cause of Type 1 diabetes is unknown, but Type 2 diabetes is caused by lifestyle changes happening daily. The prevalence rate of Type 2 diabetes has quadrupled, when compared to 40 years ago. Although oral drugs are considered as a standard care treatment for Type 2 patients, there has been a rise in the need for using insulin, along with the conventional medication, in order to help stabilize blood glucose levels. This trend has attracted many players, both local and international, to enter into the biosimilar market.
    The prevalence of Type 2 diabetes mellitus (T2DM) has increased dramatically during the last two decades, a fact driven by the increased prevalence of obesity and the primary risk factor for T2DM. Diabetes ranks among the fast-growing chronic diseases in the United States.
    India is among the top three countries with a high incidence of diabetes. Many reports and surveys have documented a drastic increase in the diabetic population based on lifestyle habits. Significant urbanization has enabled physical inactivity and diabetes is a major health concern.
    The R&D in the insulin segments are rising year-on-year, as researchers are trying to bring out the best molecule for patients’ use, curbing out maximum side effects and increasing their efficiency. Thus, the increasing prevalence of obesity and diabetes across the world is likely to augment considerable demand for insulin, which may drive the global market for insulin therapeutics.

    North America Dominates the Market

    North America dominates the global human insulin market, especially the United States, owing to the high prevalence of diabetes in the region, because of a sedentary lifestyle and launch of new drugs in the region.
    The cost factor is the major concern in the United States, where almost 50% of the insulin revenues for the manufacturers are from the country itself.
    Asia-Pacific is expected to grow tremendously during the forecast period, owing to factors, such as high prevalence of obesity and rising awareness regarding diabetes care in the region.

    Market Dynamics: –

    • Drivers: (Developing regions and growing markets)
    • Limitations: (Regional, Key Player facing Issues, Future Barriers for growth)
    • Opportunities: (Regional, Growth Rate, Competitive, Consumption)

    The report provides key statistics on the market status of the Human Insulin Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Human Insulin.

    Purchase this Report (Price 5000 USD for single user license) – https://www.industryresearch.co/purchase/13999756

    Report Objectives:

    • Analyzing the size of the Human Insulin market on the basis of value and volume.
    • Accurately calculating the market segments, consumption, and other dynamic factors of different sections of the global Human Insulin market.
    • Determining the key dynamics of the Human Insulin market.
    • Highlighting significant trends of the Human Insulin market in terms of manufacture, revenue, and sales.
    • Deeply summarizing top players of the Human Insulin market and showing how they compete in the industry.
    • Studying industry processes and costs, product pricing, and various trends related to them.
    • Displaying the performance of different regions and countries in the global Human Insulin market.

    Detailed TOC of Human Insulin Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Product Type
    5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.1.1.1 Lantus
    5.1.1.2 Levemir
    5.1.1.3 Toujeo
    5.1.1.4 Tresiba
    5.1.1.5 Basaglar
    5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2012-2024)
    5.1.2.1 NovoRapid/Novolog
    5.1.2.2 Humalog
    5.1.2.3 Apidra
    5.1.3 Traditional Human Insulins (Value and Volume, 2012-2024)
    5.1.3.1 Novolin/Actrapid/Insulatard
    5.1.3.2 Humulin
    5.1.3.3 Insuman
    5.1.4 Combination Insulins (Value and Volume, 2012-2024)
    5.1.4.1 NovoMix
    5.1.4.2 Ryzodeg
    5.1.4.3 Xultophy
    5.1.5 Biosimilar Insulins (Value and Volume, 2012-2024)
    5.1.5.1 Insulin Glargine Biosimilars
    5.1.5.2 Human Insulin Biosimilars
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States (Value and Volume, 2012-2024)
    5.2.1.1.1 Basal or Long-acting Insulins
    5.2.1.1.2 Bolus or Fast-acting Insulins
    5.2.1.1.3 Traditional Human Insulins
    5.2.1.1.4 Combination Insulins
    5.2.1.1.5 Biosimilar Insulins
    5.2.1.2 Canada (Value and Volume, 2012-2024)
    5.2.1.2.1 Basal or Long-acting Insulins
    5.2.1.2.2 Bolus or Fast-acting Insulins
    5.2.1.2.3 Traditional Human Insulins
    5.2.1.2.4 Combination Insulins
    5.2.1.2.5 Biosimilar Insulins
    5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
    5.2.1.3.1 Basal or Long-acting Insulins
    5.2.1.3.2 Bolus or Fast-acting Insulins
    5.2.1.3.3 Traditional Human Insulins
    5.2.1.3.4 Combination Insulins
    5.2.1.3.5 Biosimilar Insulins
    5.2.2 Europe
    5.2.2.1 France (Value and Volume, 2012-2024)
    5.2.2.1.1 Basal or Long-acting Insulins
    5.2.2.1.2 Bolus or Fast-acting Insulins
    5.2.2.1.3 Traditional Human Insulins
    5.2.2.1.4 Combination Insulins
    5.2.2.1.5 Biosimilar Insulins
    5.2.2.2 Germany (Value and Volume, 2012-2024)
    5.2.2.2.1 Basal or Long-acting Insulins
    5.2.2.2.2 Bolus or Fast-acting Insulins
    5.2.2.2.3 Traditional Human Insulins
    5.2.2.2.4 Combination Insulins
    5.2.2.2.5 Biosimilar Insulins
    5.2.2.3 Italy (Value and Volume, 2012-2024)
    5.2.2.3.1 Basal or Long-acting Insulins
    5.2.2.3.2 Bolus or Fast-acting Insulins
    5.2.2.3.3 Traditional Human Insulins
    5.2.2.3.4 Combination Insulins
    5.2.2.3.5 Biosimilar Insulins
    5.2.2.4 Spain (Value and Volume, 2012-2024)
    5.2.2.4.1 Basal or Long-acting Insulins
    5.2.2.4.2 Bolus or Fast-acting Insulins
    5.2.2.4.3 Traditional Human Insulins
    5.2.2.4.4 Combination Insulins
    5.2.2.4.5 Biosimilar Insulins
    5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
    5.2.2.5.1 Basal or Long-acting Insulins
    5.2.2.5.2 Bolus or Fast-acting Insulins
    5.2.2.5.3 Traditional Human Insulins
    5.2.2.5.4 Combination Insulins
    5.2.2.5.5 Biosimilar Insulins
    5.2.2.6 Russia (Value and Volume, 2012-2024)
    5.2.2.6.1 Basal or Long-acting Insulins
    5.2.2.6.2 Bolus or Fast-acting Insulins
    5.2.2.6.3 Traditional Human Insulins
    5.2.2.6.4 Combination Insulins
    5.2.2.6.5 Biosimilar Insulins
    5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
    5.2.2.7.1 Basal or Long-acting Insulins
    5.2.2.7.2 Bolus or Fast-acting Insulins
    5.2.2.7.3 Traditional Human Insulins
    5.2.2.7.4 Combination Insulins
    5.2.2.7.5 Biosimilar Insulins
    5.2.3 Latin America
    5.2.3.1 Mexico (Value and Volume, 2012-2024)
    5.2.3.1.1 Basal or Long-acting Insulins
    5.2.3.1.2 Bolus or Fast-acting Insulins
    5.2.3.1.3 Traditional Human Insulins
    5.2.3.1.4 Combination Insulins
    5.2.3.1.5 Biosimilar Insulins
    5.2.3.2 Brazil (Value and Volume, 2012-2024)
    5.2.3.2.1 Basal or Long-acting Insulins
    5.2.3.2.2 Bolus or Fast-acting Insulins
    5.2.3.2.3 Traditional Human Insulins
    5.2.3.2.4 Combination Insulins
    5.2.3.2.5 Biosimilar Insulins
    5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
    5.2.3.3.1 Basal or Long-acting Insulins
    5.2.3.3.2 Bolus or Fast-acting Insulins
    5.2.3.3.3 Traditional Human Insulins
    5.2.3.3.4 Combination Insulins
    5.2.3.3.5 Biosimilar Insulins
    5.2.4 Asia-Pacific
    5.2.4.1 Japan (Value and Volume, 2012-2024)
    5.2.4.1.1 Basal or Long-acting Insulins
    5.2.4.1.2 Bolus or Fast-acting Insulins
    5.2.4.1.3 Traditional Human Insulins
    5.2.4.1.4 Combination Insulins
    5.2.4.1.5 Biosimilar Insulins
    5.2.4.2 South Korea (Value and Volume, 2012-2024)
    5.2.4.2.1 Basal or Long-acting Insulins
    5.2.4.2.2 Bolus or Fast-acting Insulins
    5.2.4.2.3 Traditional Human Insulins
    5.2.4.2.4 Combination Insulins
    5.2.4.2.5 Biosimilar Insulins
    5.2.4.3 China (Value and Volume, 2012-2024)
    5.2.4.3.1 Basal or Long-acting Insulins
    5.2.4.3.2 Bolus or Fast-acting Insulins
    5.2.4.3.3 Traditional Human Insulins
    5.2.4.3.4 Combination Insulins
    5.2.4.3.5 Biosimilar Insulins
    5.2.4.4 India (Value and Volume, 2012-2024)
    5.2.4.4.1 Basal or Long-acting Insulins
    5.2.4.4.2 Bolus or Fast-acting Insulins
    5.2.4.4.3 Traditional Human Insulins
    5.2.4.4.4 Combination Insulins
    5.2.4.4.5 Biosimilar Insulins
    5.2.4.5 Australia (Value and Volume, 2012-2024)
    5.2.4.5.1 Basal or Long-acting Insulins
    5.2.4.5.2 Bolus or Fast-acting Insulins
    5.2.4.5.3 Traditional Human Insulins
    5.2.4.5.4 Combination Insulins
    5.2.4.5.5 Biosimilar Insulins
    5.2.4.6 Vietnam (Value and Volume, 2012-2024)
    5.2.4.6.1 Basal or Long-acting Insulins
    5.2.4.6.2 Bolus or Fast-acting Insulins
    5.2.4.6.3 Traditional Human Insulins
    5.2.4.6.4 Combination Insulins
    5.2.4.6.5 Biosimilar Insulins
    5.2.4.7 Malaysia (Value and Volume, 2012-2024)
    5.2.4.7.1 Basal or Long-acting Insulins
    5.2.4.7.2 Bolus or Fast-acting Insulins
    5.2.4.7.3 Traditional Human Insulins
    5.2.4.7.4 Combination Insulins
    5.2.4.7.5 Biosimilar Insulins
    5.2.4.8 Indonesia (Value and Volume, 2012-2024)
    5.2.4.8.1 Basal or Long-acting Insulins
    5.2.4.8.2 Bolus or Fast-acting Insulins
    5.2.4.8.3 Traditional Human Insulins
    5.2.4.8.4 Combination Insulins
    5.2.4.8.5 Biosimilar Insulins
    5.2.4.9 Philippines (Value and Volume, 2012-2024)
    5.2.4.9.1 Basal or Long-acting Insulins
    5.2.4.9.2 Bolus or Fast-acting Insulins
    5.2.4.9.3 Traditional Human Insulins
    5.2.4.9.4 Combination Insulins
    5.2.4.9.5 Biosimilar Insulins
    5.2.4.10 Thailand (Value and Volume, 2012-2024)
    5.2.4.10.1 Basal or Long-acting Insulins
    5.2.4.10.2 Bolus or Fast-acting Insulins
    5.2.4.10.3 Traditional Human Insulins
    5.2.4.10.4 Combination Insulins
    5.2.4.10.5 Biosimilar Insulins
    5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
    5.2.4.11.1 Basal or Long-acting Insulins
    5.2.4.11.2 Bolus or Fast-acting Insulins
    5.2.4.11.3 Traditional Human Insulins
    5.2.4.11.4 Combination Insulins
    5.2.4.11.5 Biosimilar Insulins
    5.2.5 Middle East & Africa
    5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
    5.2.5.1.1 Basal or Long-acting Insulins
    5.2.5.1.2 Bolus or Fast-acting Insulins
    5.2.5.1.3 Traditional Human Insulins
    5.2.5.1.4 Combination Insulins
    5.2.5.1.5 Biosimilar Insulins
    5.2.5.2 Iran (Value and Volume, 2012-2024)
    5.2.5.2.1 Basal or Long-acting Insulins
    5.2.5.2.2 Bolus or Fast-acting Insulins
    5.2.5.2.3 Traditional Human Insulins
    5.2.5.2.4 Combination Insulins
    5.2.5.2.5 Biosimilar Insulins
    5.2.5.3 Egypt (Value and Volume, 2012-2024)
    5.2.5.3.1 Basal or Long-acting Insulins
    5.2.5.3.2 Bolus or Fast-acting Insulins
    5.2.5.3.3 Traditional Human Insulins
    5.2.5.3.4 Combination Insulins
    5.2.5.3.5 Biosimilar Insulins
    5.2.5.4 Oman (Value and Volume, 2012-2024)
    5.2.5.4.1 Basal or Long-acting Insulins
    5.2.5.4.2 Bolus or Fast-acting Insulins
    5.2.5.4.3 Traditional Human Insulins
    5.2.5.4.4 Combination Insulins
    5.2.5.4.5 Biosimilar Insulins
    5.2.5.5 South Africa (Value and Volume, 2012-2024)
    5.2.5.5.1 Basal or Long-acting Insulins
    5.2.5.5.2 Bolus or Fast-acting Insulins
    5.2.5.5.3 Traditional Human Insulins
    5.2.5.5.4 Combination Insulins
    5.2.5.5.5 Biosimilar Insulins
    5.2.5.6 Rest of Middle East & Africa (Value and Volume, 2012-2024)
    5.2.5.6.1 Basal or Long-acting Insulins
    5.2.5.6.2 Bolus or Fast-acting Insulins
    5.2.5.6.3 Traditional Human Insulins
    5.2.5.6.4 Combination Insulins
    5.2.5.6.5 Biosimilar Insulins

    6 MARKET INDICATORS
    6.1 Type 1 Diabetes Population (2012-2024)
    6.2 Type 2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk AS
    7.1.2 Sanofi Aventis
    7.1.3 Eli Lilly
    7.1.4 Biocon
    7.1.5 Pfizer
    7.1.6 Julphar
    7.1.7 Exir
    7.1.8 Sedico
    7.1.9 Wockhardt
    7.2 COMPANY SHARE ANALYSIS
    7.2.1 Novo Nordisk AS
    7.2.2 Sanofi Aventis
    7.2.3 Eli Lilly
    7.2.4 Other Companies

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Textile Machine Market 2019 Robust Expansion by Top Key Manufactures | Worldwide Overview by Size, Share, Trends, Segments

    Global Fertility Tracking Apps Industry Size & Share By Sales Revenue, Demands, Growth Factors, Emerging Trends, Competitive Landscape and Forecast to 2024,

    Aircraft Tractor Market 2019 : Emerging Technologies by Industry SIze, Sales Revenue, Key Players Analysis, Development Status, Opportunity Assessment and Industry Expansion Strategies 2024

    Busbar Market 2018 Industry Overview, Key Players Analysis, Emerging Opportunities, Comprehensive Research Study, Competitive Landscape and Potential of Industry from 2018-2023

  • Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *